Research Activity – Page 2

Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine

2 weeks ago talkbio0Tagged Biotechnology, Clinical Development, Clinical Trials, Connecticut biotech, Fund Raising, hair loss treatment, Oral cavity, Phase 3, Rogaine, Veradermics

Veradermics; Connecticut biotech; oral Rogaine; Phase 3 clinical trials; fundraising; hair loss treatment; biotechnology; clinical development

Gene Therapy Delivers Long-Term Immune Protection in Children With Rare Immune Disorders

2 weeks ago talkbio0Tagged Adenosine deaminase deficiency, Clinical Trials, Combined immunodeficiency disease, Congenital leukocyte adherence deficiency, Curative Therapy, gene therapy, immune protection, Leukocyte adhesion deficiency type 1, Long-term, Pediatric immunology, Rare Diseases, Severe (severity modifier)

gene therapy; long-term immune protection; ADA-SCID; severe combined immunodeficiency; LAD-I; leukocyte adhesion deficiency; rare disease; pediatric immunology; clinical trial; curative treatment

Lilly’s Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

2 weeks ago talkbio0Tagged ACHIEVE-1, ATTAIN-2, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Effectiveness, Eli Lilly, Farxiga, Glucagon-Like Peptide 1, Oral cavity, orforglipron, regulatory submission, Safety, semaglutide, Weight Loss

Lilly; Orforglipron; oral GLP-1; type 2 diabetes; clinical trial; weight loss; regulatory submission; ACHIEVE-1; ATTAIN-2; semaglutide; Farxiga; efficacy; safety

Tubulis Secures $361 Million Series C to Advance Clinical-Stage Antibody-Drug Conjugates (ADCs)

2 weeks ago talkbio0Tagged Antibody-Drug Conjugates, cancer therapeutics, Clinical Trials, Optimization, precision oncology, Series C funding, Solid Neoplasm, therapeutic autologous dendritic cells, TUB-030, TUB-040, Tubulis

Tubulis; Series C funding; antibody-drug conjugates; ADC; precision oncology; cancer therapeutics; TUB-040; TUB-030; solid tumors; clinical trials; biotech; platform optimization

Spotlight On: Cabaletta Bio’s Small but Mighty Breakthrough for CAR-T in Autoimmune Arena

2 weeks ago talkbio0Tagged Autoimmune Diseases, B-Lymphocytes, Cabaletta Bio, CAR-T therapy, Clinical Trials, Depletion, Lupus Erythematosus, Systemic, Myositis, Pemphigus Vulgaris, Preconditioning, rese-cel, Systemic Scleroderma, United States Food and Drug Administration

Cabaletta Bio; CAR-T therapy; rese-cel; autoimmune diseases; B cell depletion; myositis; systemic lupus erythematosus; systemic sclerosis; pemphigus vulgaris; preconditioning; clinical trial; FDA

Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug

2 weeks ago talkbio0Tagged Bain Capital, clinical pipeline, Funding, GLP-1/GIP Dual Agonist, Kailera, Obesity Drug, Phase 3 Clinical Trials, Series B financing, weight loss therapy

Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

2 weeks ago talkbio0Tagged adjuvant Tecentriq, Clinical Oncology, Clinical Trials, ESMO Congress, Molecular residual disease, muscle-invasive bladder cancer, Natera, Precision Medicine, Presidential Symposium, Signatera

Natera; ESMO Congress; IMvigor011 trial; Presidential Symposium; Signatera; molecular residual disease; muscle-invasive bladder cancer; adjuvant Tecentriq; precision medicine; clinical oncology

Patient with Preexisting Immunity to AAV Vectors Granted Gene Therapy After Antibody-Depleting Agent Allowed Eligibility

3 weeks ago talkbio0Tagged AAV antibodies, antibody-chopping drug, Clinical Trials, Eligibility Determination, gene therapy

gene therapy; AAV antibodies; ineligible; antibody-chopping drug; clinical trial; eligibility

Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs

3 weeks ago talkbio0Tagged Ascenta Capital, biotechs, Clinical Trials, Early-stage, Evan Rachlin, Funds, Investments, multi-medicine platforms, portfolio companies, venture capital

Ascenta Capital; biotech investment; venture capital; $325M fund; clinical trials; multi-medicine platforms; Evan Rachlin; Lorence Kim; early-stage biotechs; portfolio companies

AI is Transforming Drug Safety—But Governance Sets Essential Guardrails

3 weeks ago talkbio0Tagged Adverse reaction to drug, AI guardrails, Artificial Intelligence, Bias (Epidemiology), Data Integrity, drug safety, Jeavons syndrome, patient safety, Pharmacovigilance, regulatory governance, United States Food and Drug Administration

artificial intelligence; drug safety; pharmacovigilance; adverse drug events; regulatory governance; FDA; EMEA; AI guardrails; data integrity; bias; patient safety